| L - Antineoplastic and Immunomodulating Agents | This group comprises preparations used in the treatment of neoplastic diseases, and immunomodulating agents.
Corticosteroids for systemic use, see H02.
|
|
| L04 - Immunosuppressants | Immunosuppressants are defined as agents that completely or partly suppress one or more factors in the immunosystem.
|
|
| L04A - Immunosuppressants | This group comprises immunosuppressants excl. corticosteroids.
| The DDDs are based on prophylaxis of allograft transplant rejection if this is an approved indication.
|
|
| L04AH - Mammalian Target Of Rapamycin (Mtor) Kinase Inhibitors | Oral formulations of sirolimus used in organ transplantation are classified in this group, while parenteral and topical dermatological formulations used for neoplastic diseases are classified in L01EG.
|
|
| L04AH01 - Sirolimus | | Dose | Route of administration | Note |
|---|
| | O | |
|
|
